WO2000001440A3 - Methods for treating neurological injuries and disorders - Google Patents
Methods for treating neurological injuries and disorders Download PDFInfo
- Publication number
- WO2000001440A3 WO2000001440A3 PCT/US1999/015106 US9915106W WO0001440A3 WO 2000001440 A3 WO2000001440 A3 WO 2000001440A3 US 9915106 W US9915106 W US 9915106W WO 0001440 A3 WO0001440 A3 WO 0001440A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- disorders
- treating neurological
- neurological injuries
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002336718A CA2336718A1 (en) | 1998-07-06 | 1999-07-02 | Methods for treating neurological injuries and disorders |
AU53902/99A AU771437B2 (en) | 1998-07-06 | 1999-07-02 | Methods for treating neurological injuries and disorders |
KR1020017000235A KR20010079503A (en) | 1998-07-06 | 1999-07-02 | Methods for treating neurological injuries and disorders |
JP2000557884A JP2002519394A (en) | 1998-07-06 | 1999-07-02 | Methods for treating nerve damage and disorders |
EP99939649A EP1094863A4 (en) | 1998-07-06 | 1999-07-02 | Methods for treating neurological injuries and disorders |
US09/756,481 US6872698B2 (en) | 1998-07-06 | 2001-01-08 | Methods for treating neurological injuries and disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9179198P | 1998-07-06 | 1998-07-06 | |
US60/091,791 | 1998-07-06 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/756,481 Continuation US6872698B2 (en) | 1998-07-06 | 2001-01-08 | Methods for treating neurological injuries and disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000001440A2 WO2000001440A2 (en) | 2000-01-13 |
WO2000001440A3 true WO2000001440A3 (en) | 2000-04-20 |
Family
ID=22229675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/015106 WO2000001440A2 (en) | 1998-07-06 | 1999-07-02 | Methods for treating neurological injuries and disorders |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1094863A4 (en) |
JP (1) | JP2002519394A (en) |
KR (1) | KR20010079503A (en) |
AU (1) | AU771437B2 (en) |
CA (1) | CA2336718A1 (en) |
WO (1) | WO2000001440A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1439191T1 (en) * | 2004-01-19 | 2006-06-30 | Ares Trading Sa | Process for the purification of bacterially expressed proteins |
WO2008133141A1 (en) * | 2007-04-24 | 2008-11-06 | Toyo Boseki Kabushiki Kaisha | Osmotin recombinant protein, method for production of the same, and use of the same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635372A (en) * | 1995-05-18 | 1997-06-03 | Genetics Institute, Inc. | BMP-15 compositions |
US5652118A (en) * | 1991-03-11 | 1997-07-29 | Creative Biomolecules, Inc. | Nucleic acid encoding a novel morphogenic protein, OP-3 |
US5767252A (en) * | 1996-04-08 | 1998-06-16 | The Johns Hopkins University School Of Medicine | Neuronal cell growth factor, Narp |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992000382A1 (en) * | 1990-06-15 | 1992-01-09 | Carnegie Institution Of Washington | Gdf-1 |
-
1999
- 1999-07-02 AU AU53902/99A patent/AU771437B2/en not_active Ceased
- 1999-07-02 EP EP99939649A patent/EP1094863A4/en not_active Withdrawn
- 1999-07-02 CA CA002336718A patent/CA2336718A1/en not_active Abandoned
- 1999-07-02 JP JP2000557884A patent/JP2002519394A/en active Pending
- 1999-07-02 KR KR1020017000235A patent/KR20010079503A/en not_active Application Discontinuation
- 1999-07-02 WO PCT/US1999/015106 patent/WO2000001440A2/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5652118A (en) * | 1991-03-11 | 1997-07-29 | Creative Biomolecules, Inc. | Nucleic acid encoding a novel morphogenic protein, OP-3 |
US5635372A (en) * | 1995-05-18 | 1997-06-03 | Genetics Institute, Inc. | BMP-15 compositions |
US5767252A (en) * | 1996-04-08 | 1998-06-16 | The Johns Hopkins University School Of Medicine | Neuronal cell growth factor, Narp |
Non-Patent Citations (2)
Title |
---|
FARKAS ET AL.: "Characterization of growth/differentiation factor 5 (GDF-5) as a neurotrophic factor for cultured neurons from chicken dorsal root ganglia", NEUROSCI. LETT., vol. 236, 1997, pages 120 - 122, XP002926436 * |
See also references of EP1094863A4 * |
Also Published As
Publication number | Publication date |
---|---|
KR20010079503A (en) | 2001-08-22 |
JP2002519394A (en) | 2002-07-02 |
EP1094863A2 (en) | 2001-05-02 |
AU771437B2 (en) | 2004-03-25 |
AU5390299A (en) | 2000-01-24 |
CA2336718A1 (en) | 2000-01-13 |
WO2000001440A2 (en) | 2000-01-13 |
EP1094863A4 (en) | 2005-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002036829A3 (en) | Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries | |
WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
AU2001273574A1 (en) | Substituted 5-alkynyl pyrimidines having neurotrophic activity | |
EP1140104A4 (en) | Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases | |
WO2004060146A3 (en) | Method of treatment for central nervous system injury | |
EP0792156A4 (en) | Methods for the prevention or treatment of vascular hemorrhaging and alzheimer's disease | |
BRPI0417959A (en) | antibody or functional fragment thereof, pharmaceutical composition, method for treating or prophylaxis of stroke and other neurological disorders / disorders in a human, use of an anti-goat antibody, and methods for inhibiting neurodegeneration and / or promoting recovery function in a human patient, to promote axonal growth, to produce an antifungal antibody and to produce an intravenously administered pharmaceutical composition | |
WO2005006945A3 (en) | Methods for treating neural disorders and compounds useful therefor | |
WO2004096216A3 (en) | Use of a topical medicament comprising riluzole | |
AU4331400A (en) | Neurotrophic substituted pyrimidines | |
WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
WO2004110360A3 (en) | Proteoglycan degrading mutants for treatment of cns | |
WO2005067908A3 (en) | Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease | |
WO1999060021A3 (en) | Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system | |
WO2000033814A3 (en) | Method for administering agents to the central nervous system | |
WO2000066068A3 (en) | Method for inducing growth and enhancing survival of nervous tissue | |
WO2005014041A3 (en) | Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases | |
IL171384A (en) | Use of slurp-1 in the preparation of medicaments for the treatment of neurological disorders | |
BG104466A (en) | Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration | |
WO2000057865A3 (en) | Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation | |
WO2000012045A3 (en) | Method for treating neurodegenerative disorders | |
AP9901473A0 (en) | Use of benzopyranols to treat neurological disorders. | |
WO2000009098A3 (en) | Method for treating ocular neovascular diseases | |
WO2005046605A3 (en) | Compositions and methods of treating neurological diseases | |
WO1999056666A8 (en) | The treatment of sexual dysfunction in certain patient groups |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2336718 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017000235 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 557884 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 53902/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999939649 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999939649 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017000235 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020017000235 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 53902/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999939649 Country of ref document: EP |